🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526403-30-00
Authorised Phase I

A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and its Metabolites in Healthy Participants

2026-526403-30-00 · tracked via the Priya Life Science EU tracker
Sponsor
Merck Healthcare KGaA
Sponsor type
Pharmaceutical company
Therapeutic area
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Decision date
12/08/2026
Enrollment target
17
Sites
Germany

Condition studied

This clinical trial is performed in healthy participants; the planned indication is: Neurofibromatosis Type I

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526403-30-00 on CTIS ↗ ← All trials in the EU